MedTrace Logo

3DCRT vs. IMRT in Early Breast Cancer

NCT02440191 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2017-06-05

No results posted yet for this study

Summary

It has been not clinically determined whether TomoDirect was dosimetrically better than 3D-CRT for Asian patients with early breast cancer. Therefore, the objective of this study was to compare dosimetric parameters of TomoDirect and 3D-CRT in early breast cancer patients of an Asian cohort.

Conditions

  • Radiation Toxicity

Interventions

RADIATION

3DCRT

conventional radiotherapy

Sponsors & Collaborators

  • Jong Hoon Lee

    lead OTHER

Principal Investigators

  • Jong Hoon Lee, MD · St. Vincent's Hospital, The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440191 on ClinicalTrials.gov